Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Commiphora”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

126 records · Page 7Linked to original sources
PubMed2003

Treatment of Egyptian dicrocoeliasis in man and animals with Mirazid.

Two human cases with dicrocoeliasis dendriticum were successfully treated one with Praziquantel (25mg/kg 3 times daily after meals, for four successive days) and second with Mirazid (2 capsules of 300 mg. each, daily an hour before breakfast, for six successive days) as indicated clinically and parasitologically. On the other hand, one imported sheep and two locally bred goats naturally infected with D. dendriticum were successfully treated with Oleo-resin solution (dose of 6 ml of 10 gm% equal to 2 Mirazid capsules before breakfast) per os once daily for four successive days. The animals were slaughtered on 5th day. Mirazid (capsule or Oleo-resin solution) was effective against dicrocoeliasis in man and animal respectively.

Animals↗
PubMed2003

Role of circulating Fasciola antigens and IgG4 isotype in assessment of cure from fascioliasis.

Sixty-eight individuals were included in this study, 30 of them presented with Fasciola infection, 20 were infected with other parasites but not Fasciola (infected control group) and 18 individuals were parasite-free (normal control group). For all groups, stool analysis by modified formol-ether technique and Kato thick smears for egg counts and the circulating Fasciola antigens (CFAgs) and anti- Fasciola IgG4 isotype were estimated by ELISA technique. Complete blood count, liver functions tests and abdominal ultra-sonography were performed for all Fasciola-infected patients. Patients with fascioliasis received a myrrh-derived drug (Mirazid) in a dose of 10 mg/kg b.wt., one hour before breakfast for six consecutive days. Remeasuring of the above parameters was performed one and three months after therapy. Detection of CFAgs was found to be a useful marker for assessment of core. No cross reaction was observed between Fasciola and other parasites by using CFAg (100% specificity). The level of these antigens correlated positively with signs of cure; parasitologically, clinically or ultrasonographically. Detection of IgG4 isotype was found to be a more sensitive and accurate immunodignostic tool for fascioliasis, but it was not a useful marker for assessment of cure. Mirazid drug possesses high therapeutic efficacy (100% cure rate) on fascioliasis without remarkable side effects.

Adolescent↗
PubMed1989

Clinical trials with gugulipid. A new hypolipidaemic agent.

Multicentric clinical trials of the efficacy of gugulipid conducted at Bombay, Bangalore, Delhi, Jaipur, Lucknow, Nagpur and Varanasi have been reported. Two hundred and five patients completed 12 week open trial with gugulipid in a dose of 500 mg tds after 8 week diet and placebo therapy. One patient showed gastrointestinal symptoms which did not necessitate withdrawal of the drug. A significant lowering of serum cholesterol (av. 23.6%) and serum triglycerides (av. 22.6%) was observed in 70-80% patients Double-blind, crossover study was completed in 125 patients with gugulipid therapy and in 108 patients with clofibrate therapy. Two patients had flu-like syndrome with clofibrate and opted out from the study. With gugulipid the average fall in serum cholesterol and triglycerides was 11 and 16.8% respectively and with clofibrate 10 and 21.6% respectively. The lipid lowering effect of both drugs became evident 3-4 week after starting the drug and had no relationship with age, sex, and concomitant drug intake. Hypercholesterolaemic patients responded better to gugulipid therapy than hypertriglyceridaemic patients who responded better to clofibrate therapy. In mixed hyperlipidaemic patients response to both drugs was comparable. HDL-cholesterol was increased in 60% cases who responded to gugulipid therapy. Clofibrate had no effect on HDL-cholesterol. A significant decrease in LDL-cholesterol was observed in the responder group to both drugs.

Adult↗
PubMed1995

Antiperoxide effects of S-allyl cysteine sulphoxide isolated from Allium sativum Linn and gugulipid in cholesterol diet fed rats.

Cholesterol containing diet significantly increased not only the body weight, but also the weight of liver and adipose tissue of rats. This is accompanied by a significant increase in blood lipids, atherogenic index and lipid peroxidation and a significant decrease in reduced glutathione level, superoxide dismutase and catalase activities in tissues. Treatment with S-allyl cysteine sulphoxide reverses the deleterious effects of cholesterol diet significantly and almost as effectively as gugulipid.

Allium↗
PubMed1994

Effect of gugulipid on bioavailability of diltiazem and propranolol.

The effect of single oral dose of 1 gm gugulipid was studied on bioavailability of single oral dose of propranolol (40 mg) and diltiazem (60 mg) in 10 and 7 normal healthy male volunteers respectively. It was a randomised within group crossover study. Blood samples were collected at hourly intervals upto 8 hrs. Gugulipid significantly reduced (P < .01) peak plasma concentration (Cmax) and area under curve (AUC 0-8 hrs) of both the drugs in normal volunteers. Such interaction in patients receiving propanolol or diltiazem with gugulipid may lead to diminished efficacy or nonresponsiveness due to significant reduction in bioavailability.

Administration, Oral↗
PubMed1995

Effects of S-allyl cysteine sulfoxide isolated from Allium sativum Linn and gugulipid on some enzymes and fecal excretions of bile acids and sterols in cholesterol fed rats.

S-allyl cysteine sulfoxide, isolated from garlic, A. sativum, is more or less as active as gugulipid in controlling hypercholestermia, obesity and derangement of enzyme activities in cholesterol diet fed rats. The beneficial effects of the drugs are partly due to their inhibitory effects on transaminases, alkaline phosphatase, lipogenic enzymes and HMG CoA reductase and partly due to their stimulatory effects on plasma lecithin-cholesterol acyl transferase lipolytic enzymes and fecal excretion of sterols and bile acids.

Animals↗